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Objective: The aim of this study was to assess the predictive value of microvascular abnormalities and lipofuscin
observed in endomyocardial biopsy samples for the development of cardiac allograft vasculopathy.
Methods: The study group consisted of 68 cardiac allograft recipients (63 men and 5 women, 43 12 years old).
We performed a re-evaluation of 1071 endomyocardial biopsy specimens to search for microvascular diseases
and lipofuscin in cardiocytes. Endomyocardial biopsy specimens with an International Society for Heart and
Lung Transplantation rejection grade of 2 or more and those without arterioles were excluded. Abnormalities
found in the remaining 517 specimens were correlated with the grade of rejection. Biopsy specimens obtained
2 weeks, 12 months, and 36 months after transplantation were compared with coronary angiography results, clin-
ical events of cardiac allograft vasculopathies, and survivals. Kaplan–Meier curves were constructed to compare
the time to the development of cardiac allograft vasculopathy or death.
Results: Enlarged endothelial cells, lymphocytes inside the arteriolar wall, occluded arteriolar lumen, endothelial
vacuolization, and hypertrophy of the vascular muscle were significantly correlated with rejection grade.
Although none of the vascular abnormalities predicted cardiac allograft vasculopathy, patients with lipofuscin
deposits at the 12-month biopsy specimens were characterized by the rapid development of angiography-
confirmed cardiac allograft vasculopathy (P< .08) and events related to cardiac allograft vasculopathy (P<
.03, log–rank test).
Conclusion: Microvascular abnormalities correlate with mild cellular rejection, but they do not seem to be pre-
dictive for development of cardiac allograft vasculopathy detected by angiography. The presence of lipofuscin in
12-month endomyocardial biopsy specimens may be predictive of development of angiographically confirmed
cardiac allograft vasculopathy.T
XSupplemental material is available online.
Cardiac allograft vasculopathy (CAV) is, apart from malig-
nancy, the predominant cause of death in heart transplant re-
cipients 3 or more years after heart transplantation.1 Intimal
hyperplasia, which begins in the narrowest parts of distal ar-
terioles, and shrinkage of the whole vessel are the most char-
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doi:10.1016/j.jtcvs.2009.02.040The Journal of Thoracic and Cacteristic features of coronary artery lumen loss. However,
a typical atherosclerotic plaque localized in the large epicar-
dial vessels is also a frequent type of lesion.2,3 Despite signif-
icant differences between CAV features in large and small
coronary vessels, an attempt is being made to find a common
pathogenic mechanism for transplanted heart coronary artery
disease, in which endothelial damage and inflammatory pro-
cesses stimulating myofibroblast proliferation and fibrosis
are the pivotal processes.4 The influence of nonimmunologic
risk factors on the development of disease in transplanted
heart coronary arteries is well documented,5,6 whereas
evidence connecting acute rejection and CAV is rather
weak.1,7-9 The main problem is an inability to separate the
immunologic phenomena characterizing rejection from the
pro-atherosclerotic side effects of high-dose immunosup-
pressive therapy, which has to be increased to control rejec-
tion.
There is no ideal method for monitoring CAV. Although
coronary angiography (CAG) is not sensitive enough for di-
agnosing intimal hyperplasia, it is the most frequently used
clinical tool for diagnosing CAV. Intravascular ultrasound
is able to show the vessel wall structure, but it is limited to
relatively large coronary arteries owing to the size of theardiovascular Surgery c Volume 138, Number 1 215
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AR ¼ acute cellular rejection
CAG ¼ coronary angiography
CAV ¼ cardiac allograft vasculopathy
EMB ¼ endomyocardial biopsy
ISHLT ¼ International Society for Heart and
Lung Transplantation
OHT ¼ orthotopic heart transplantation
ultrasound probe. Owing to the high cost, the technical
complexity, and the need for higher doses of nephrotoxic
contrast substances, intravascular ultrasound remains a re-
search tool rather than a clinical practice. In routine endo-
myocardial biopsy (EMB), a variety of pathomorphologic
changes in small cardiac vessels can be observed. The pres-
ence of arterioles in EMB samples is incidental; however, an
analysis of microvascular alterations may shed light on CAV
pathogenesis. Some articles suggest a leading role for immu-
nologic factors in the development of small vessel disease of
the transplanted heart.10,11
There is a growing interest in the role of aging markers in
the pathogenesis of heart failure, including disease of the
transplanted heart. Lipofuscin, an age pigment, is a nonde-
gradable intralysosomal polymeric substance composed of
oxidized proteins, lipids, and trace amounts of metals. It is
mostly accumulated in long-living cells, such as cardiomyo-
cytes and neurons, as a result of normal cell metabolism. Cell
turnover is increased by stress factors, such as ischemia or in-
flammation, which consequently accelerate the accumulation
of lipofuscin and other waste material, but no immunologic
mechanism for the increase in lipofuscin deposit formation
has yet been described.12,13 Autophagy, an intralysosomal
degradation of a cell’s own organelles, plays an important
role in lipofuscin accumulation and cell renewal.14
The aim of this study was to determine whether vascular
abnormalities and lipofuscin deposition in the cytoplasm of
cardiomyocytes have any predictive value for the develop-
ment of CAV.
MATERIAL AND METHODS
We re-evaluated all available EMB slides of patients in whom heart trans-
plantation was performed in the Silesian Center for Heart Disease before the
end of 1995, specifically searching for abnormalities in small arterial coro-
nary vessels and lipofuscin deposits in the cytoplasm of cardiomyocytes.
Inclusion criteria were as follows: orthotopic heart transplantation
(OHT) performed before the end of 1995, EMB performed 2 weeks after
OHT and at the 12th and 36th months after OHT in patients eligible from
the study, and at least one CAG performed after OHT. Among 197 patients
who underwent OHT from 1986 to 1995, 68 patients were enrolled for this
retrospective study. The majority of the remaining patients were excluded
owing to early loss and the lack of at least one CAG. The study group con-
sisted of 63 men and 5 women, with a mean age of 43 12 years. All donors
were below 35 years old, and head trauma was a predominant cause of
death. The presence of the following ‘‘classic’’ risk factors for atheroscle-216 The Journal of Thoracic and Cardiovascular Surosis was identified in the study group: male sex in 63 (93%) patients, age
over 40 years in 47 (69%) patients and age over 50 years in 21 (31%) pa-
tients, ischemic cardiomyopathy as an indication for OHT in 35 (51%) pa-
tients, body mass index over 25 kg/m2 in 34 (50%) patients, diabetes
mellitus before and/or after OHT in 11 (16%) patients, arterial hypertension
in 30 (44%) patients, and some form of hyperlipidemia in 45 (66%) patients.
Immunosuppression was based on a triple-drug protocol with cyclospor-
ine A, azathioprine, and prednizone. No elective cytolytic induction therapy
was used. Mycophenolate mofetil, available since 1996, replaced azathio-
prine after the second episode of significant acute cellular rejection (AR).
3-Hydroxy-3-methylglutaryl coenzyme A reductaze inhibitors (statins)
were used only on diagnosis of hyperlipidemia.
Elective EMB specimens were obtained at 1, 2, 3, 4, 6, and 8 weeks and
3, 6, 9, 12, and 18 months after OHT. The overall number of specimens con-
sidered for the purpose of this study was 1071.
AR was assessed by the grading system developed by the International
Society for Heart and Lung Transplantation (ISHLT), with grades of 3A or
greater recognized as significant and treated with bolus doses of methylpred-
nisolone succinate (SoluMedrol), 1.0 g daily for 3 days, and subsequent ther-
apy with a tapered dose of prednisone, starting at 1.0 mg/kg of body weight.
The following numeric values for ISHLT grades were used in the analyses:
0 ¼ 0 point; 1A ¼ 1 point; 1B ¼ 2 points; 2 ¼ 3 points; 3A ¼ 4 points; 3B
¼ 5 points; and 4 ¼ 6 points. The average biopsy score was 2.27  0.57.
The average number of significant rejection episodes per patient was 2.5 1.8.
Increased predisposition toward AR was recognized in patients who had
more than 2 episodes of significant AR (20 individuals; 29%) and/or in pa-
tients with at least 1 episode of AR occurring more than 1 year after OHT
(18 individuals; 26%).
Vessel abnormalities were assessed in EMB samples with an ISHLT re-
jection grade of 1B or less. EMB specimens with an ISHLT rejection grade
of 2 or more and without arterioles were excluded from further investiga-
tion. From the 1071 EMB samples, we selected 517 (48%) samples fulfilling
these criteria, in which vessel abnormalities and lipofuscin deposits were as-
sessed. Hematoxylin and eosin staining was performed according to stan-
dard protocols. Additionally, selected slides were stained with Masson
trichrome to assess interstitial fibrosis and myocytolysis. We assessed the
following vessel abnormalities: presence of prominent endothelial cells, de-
generation of the endothelium, thickening of the muscular layer, thickening
of the vascular wall (basal membrane and muscle layer), presence of lym-
phocytes in the arteriolar wall without any other signs of rejection vasculitis,
periarteriolar fibrosis, and an occluded arteriolar lumen (Figure E1). Addi-
tionally, the same biopsy slides were evaluated for the presence of lipofuscin
(Figure E2). Lipofuscin deposits were visualized as bright yellow autofluor-
escent granules under ultraviolet light using an epifluorescence microscope.
The presence of particular vascular abnormalities and lipofuscin deposits
in the selected set of 517 EMB samples was correlated with the grade of re-
jection (ISHLT grade 0–1B), using the R Spearman test. Biopsy specimens
obtained 2 weeks after OHT and 12 and 36 months after OHT (or the closest
time) were compared with the occurrence of the following:
 Any CAV confirmed by CAG, that is, the presence of critical and
noncritical coronary stenosis observed in the main vessels, as
well as in the primary and secondary branches, and/or features
characteristic of distal vessel occlusion (slow passage of contrast
through the vessels, lack of small vessels in the background for
primary arteries and branches, significantly smaller than the ex-
pected diameter of the vessel lumen)
 Significant CAV, that is, the presence of hemodynamically sig-
nificant coronary stenosis requiring coronary angioplasty, any
critical stenosis (90% diameter stenosis) in the main coronary
artery or the primary and secondary branch, myocardial infarc-
tion, or death caused by CAV)
 Death from all causes.rgery c July 2009
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utive CAGs were performed at least every 24 months.
EMB samples were reviewed by two experienced pathologists who were
blinded to the CAG results, and each CAG was read by at least two invasive
cardiologists who were not informed of the EMB results.
Continuous variables were presented as mean  SD. Spearman coeffi-
cients and P values were calculated to estimate the correlation between
the grade of AR and vascular abnormalities found in EMB samples. Odds
ratios and 95% confidence intervals were calculated to assess the probability
of developing any CAV, significant CAV, or death from any cause depend-
ing on the presence of classic risk factors of atherosclerosis and EMB find-
ings. Kaplan–Meier curves were constructed to compare the time to CAV
development in patients with and without lipofuscin deposits and particular
vascular abnormalities. Significance values were calculated by log–rank
tests (P>.1 was marked as NS). Follow-up was completed on January
31, 2006.
RESULTS
The correlations between the rejection grade and the pres-
ence versus absence of vascular abnormalities are listed in
Table 1. Five of seven analyzed vascular features were found
to be significantly related to cellular rejection: occurrence of
enlarged endothelial cells, presence of single lymphocytes
inside the arteriolar wall, occluded arteriolar lumen, puncti-
form endothelial vacuolization, and the presence of vascular
muscle hypertrophy. There was no correlation between the
presence of lipofuscin and rejection grade.
CAV was confirmed by CAG in 42 (62%) patients, CAV-
related clinical events were observed in 23 (34%) patients,
and death occurred in 35 (51%) patients. Analysis of odds
ratios for classic risk factors of atherosclerosis, markers of
high predisposition towards AR, particular vascular abnor-
malities, and the presence of lipofuscin in EMB samples re-
vealed that none of these factors significantly increased the
probability of any CAV or significant CAV development.
The presence of periarteriolar fibrosis in the 3-year EMB in-
creased the probability of death, and enlarged endothelial
cell occurrence decreased the risk of death (Table E1).
Comparisons of the survival time after OHT without any
CAV, with significant CAV, and death from any cause with
particular vascular diseases in the 2-week, 12-month, and
36-month EMB samples are listed in Table 2. The only vas-
cular abnormality observed in the 2-week EMB specimens
predicting shorter time to the CAV-related clinical events
was the presence of lymphocytes in the arterial wall. An-
other significant difference was found between patients
with and without thickening of the vascular wall 12 months
after OHT; the only 2 patients with this feature both had sig-
nificant CAV before the end of the seventh year after OHT.
None of the vascular abnormalities observed in the 2-week
or 12-month EMB specimens predicted a shorter survival
time, whereas a significant increase in survival time was
found in patients without periarteriolar fibrosis in the 36-
month EMB sample (Figure E3).
Lipofuscin was found in 23 (34%) patients in the 12-month
EMB sample and in 30 (47%) patients in the 36-month EMBThe Journal of Thoracic and Csample. Of the 20 patients positive for lipofuscin in the 1-year
EMB specimen for whom 36-month EMB samples were
available for analysis, lipofuscin was observed in 15 (75%).
Patients with lipofuscin in the 12-month EMB sample were
characterized by a faster development of CAV (P<.08), sig-
nificant CAV (P<.03), and survival (P<.07, log–rank test)
(Figure 1). This relationship was not observed with lipofuscin
positive samples in the 36-month EMB samples (Figure 2).
Lipofuscin was also present in the 2-week EMB samples
of 2 patients; 12-month and 36-month EMB samples of these
patients were lipofuscin negative.
DISCUSSION
The potential relationship between AR and CAV, detected
both by angiography and by microvasculopathy in EMB
samples, remains controversial. Some degree of vasculitis,
which is typical of lymphocyte migration into the myocar-
dium during AR, seems to be reversible. Its presence in
EMB samples is not synonymous with the preclinical phase
of CAV. For this reason, some studies analyze vascular ab-
normalities only in ISHLT grade 0 EMB specimens, and
we do not disagree with this approach.10 However, the
limitation of this study to patients with no signs of AR in
the 1- and 3-year EMBs would exclude the majority of those
enrolled from further investigation. We decided to exclude
only EMB specimens with active myocytolysis of ISHLT
grade 2 and higher. We confirmed a relationship between
lower grades of AR and the majority of pathologic micro-
vasculature features, suggesting that some of these may be
reversible. This may be due to the lack of relationship
between early microvasculopathy and late disease of epicar-
dial coronary vessels. However, our results do agree with
reports that revealed a relationship between microvasculop-
athy and a history of AR, even in EMB specimens without
any signs of current active rejection, which shows that a poten-
tial bias from AR is not easily eliminated.10 On the other hand,
we did not find any relationship between microvascular dis-
ease and epicardial coronary artery disease, even when only
AR-independent features were taken into consideration.
TABLE 1. Correlations between the rejection grade and presence
versus absence of vascular abnormalities (Spearman coefficients)
based on an analysis of 517 EMB samples with an ISHLT rejection
grade of 1B or less and arterioles suitable for analysis
Vascular abnormalities R value, P value
Presence of prominent endothelial cells R ¼ 0.44, P< .001
Degeneration of endothelium R ¼0.19, P< .001
Thickening of muscle layer R ¼0.20, P< .001
Thickening of basal membrane and muscle layer NS
Presence of lymphocytes in arteriolar wall R ¼ 0.44, P< .001
Periarteriolar fibrosis NS
Occluded arteriolar lumen R ¼ 0.79, P< .001
EMB, Endomyocardial biopsy; ISHLT, International Society for Heart and Lung
Transplantation; R, Spearman coefficient; NS, not significant.ardiovascular Surgery c Volume 138, Number 1 217
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.218 The Journal of Thoracic and Cardiovascular SWe were unable to detect any correlation between the ab-
normalities in microvasculature analyzed in this study and
epicardial CAV. This hypothetical relationship was absent
not only 12 months after transplantation, but also when com-
paring EMB and CAG results 3 years after transplantation (ie,
when epicardial lesions are not infrequent). Although corre-
lating the EMB vascular changes with clinical CAV remains
controversial,15 we agree with the reports that challenge the
diagnostic value of EMB in predicting or confirming epicar-
dial coronary artery disease.16,17 It is worth emphasizing
that it is easier to show the relationship between miscrovascul-
opathy and AR, or even survival, than it is to correlate miscro-
vasculopathy with epicardial coronary disease.11
None of the early (12-month) vascular diseases were pre-
dictive for decreased survival time, and the only feature dis-
criminating patients with shorter survival times from those
with increased survival was periarteriolar fibrosis observed
in the 36-month EMB samples. This pathologic condition
was not correlated with the degree of AR, and its role in
the pathogenesis of transplanted heart failure should be in-
vestigated further.
Myocardial cellular senescence is accompanied by lipofus-
cin accumulation (aggregates of oxidized and cross-linked
insoluble proteins). Lipofuscin formation depends on the
oxidation of mitochondrial proteins produced by oxidative
stress. As such, ischemic and rejection episodes may play
an important role in lipofuscin deposition.18 Roffe19 identifies
lipofuscin deposition, interstitial cardiac fibrosis, relative car-
diocyte hypertrophy, and lower capillary density as indicative
of age-related heart histology. The three former changes are
most frequent in posttransplant heart biopsy tissue, and the de-
creased density of capillaries results from CAV. Lipofuscin
deposits can also play a role in the regulation of cellular ho-
meostasis by inducing apoptosis.20 Thus, attempts to uncover
links between CAV, the presence of lipofuscin, and the clin-
ical course are promising avenues of research.
In contrast to vascular disease, lipofuscin deposition in the
cytoplasm of cardiocytes observed 12 months after trans-
plantation seems to be a good predictor of CAV develop-
ment. This observation has interesting implications;
particularly, since lipofuscin is a marker of aging, the mech-
anism of CAV development may include elements of accel-
erated aging occurring in the allograft during the first 12
months after transplantation, and rapid aging after the proce-
dure may indicate development of CAV. Endothelial cell
degradation is thought to be the critical stage for vasculop-
athy development—further disease is a result of the undesir-
able repair mechanisms involving myocyte migration and
proliferation and resulting in neointima formation.4 We hy-
pothesize that early cardiocyte aging could be related to the
rapid endothelial degradation that provokes those repair pro-
cesses. Why the first year after OHT is so important is a phe-
nomenon that awaits explanation, but it has been shown that
1-year intimal growth is a marker of poor prognosis.21,22urgery c July 2009
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Zakliczynski et al Cardiothoracic TransplantationFIGURE 1. Comparison of the time free from the development of any angiographically confirmed CAV (A), significant CAV (B), and survival (C) in pa-
tients with and without lipofuscin deposits presence in cytoplasm of cardiocytes observed in the 12th-month EMB specimen. CAV, Cardiac allograft vascul-
opathy; EMB, endomyocardial biopsy; OHT, orthotopic heart transplantation; TxCAD, transplant coronary artery disease; MI, myocardial infarction; CAG,
coronary angiography.Notably, the same marker of aging observed 3 years after
OHT seems to have no predictive value for CAV develop-
ment and death. Lipofuscin deposition is more common atThe Journal of Thoracic and Cthis time (in almost half of the patients, compared with
only one third of OHT recipients at the end of the first
year after transplantation), but only 75% of the individualsardiovascular Surgery c Volume 138, Number 1 219
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Cardiothoracic Transplantation Zakliczynski et alFIGURE 2. Comparison of the time free from the development of any angiographically confirmed CAV (A), significant CAV (B), and survival (C) in pa-
tients with and without lipofuscin deposits present in the cytoplasm of cardiocytes observed in the 36th month EMB specimen. CAV, Cardiac allograft vas-
culopathy; EMB, endomyocardial biopsy; OHT, orthotopic heart transplantation; TxCAD, transplant coronary artery disease; MI, myocardial infarction; CAG,
coronary angiography; PCI, percutaneous coronary intervention; NS, not significant.with lipofuscin in the 1-year EMB results remained positive
2 years later. Additionally, patients with lipofuscin present
in EMB samples obtained 2 weeks after OHT showed an ab-220 The Journal of Thoracic and Cardiovascular Surgsence of lipofuscin at 12 and 36 months after OHT. Specif-
ically, 25% of patients with lipofuscin-positive EMBs 12
months after OHT did not show this marker 2 years later.ery c July 2009
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that allowed the examination of the same EMB slides that
were used to assess a rejection grade at a time of procure-
ment, inasmuch as there was no any additional tissue mate-
rial that could be used for more specific identification of
lipofuscin. A method of identifying lipofuscin using its au-
tofluorescent properties is widely accepted and used in
many areas of histologic investigation.
The issue of lipofuscin elimination itself seems to be very
interesting. Early death of cells with lipofuscin deposits is
not the only mechanism for clearance; a lipofuscin elimina-
tion mechanism was described in retinal pigment epithelium
in 1999,23 which implicated protease inhibition in lipofuscin
disposal. Although we do not as yet have direct evidence for
enhanced lysosomal activity in postmitotic transplanted car-
diomyocytes, we postulate that the intracellular metabolic
pathway activity would be increased during myocardial re-
modeling.
Our study is the first attempt to correlate lipofuscin depo-
sition in cardiomyocytes with CAV; the only previous pub-
lication confirming the presence of lipofuscin in transplanted
heart myocytes does not examine this process in the context
of CAV.24
Two major limitations of this study are its retrospective
nature and the low number of observed subjects, which
may bias statistical testing. The necessity to use EMB slides
with rejection grades higher than 0, according to the ISHLT,
was mentioned earlier. Intravascular coronary ultrasound
was not used in the majority of patients, so it was not possi-
ble to use these results to standardize a diagnosis of CAV.
Additionally, the category of any CAV was biased by the
lack of routine CAG performed in the donor or immediately
after the OHT to exclude coronary disease in the donor at the
time of the investigation. All of these limitations should be
taken into account when planning larger prospective trials
to confirm the results of this study.
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Zakliczynski et al Cardiothoracic TransplantationFIGURE E2. Lipofuscin in the cytoplasm of cardiocytes, assessed under
fluorescent microscope (lipofuscin in yellow).
FIGURE E3. Comparison of the survival time in patients with and without periarteriolar fibrosis observed in the 36th-month EMB specimen. EMB, Endo-
myocardial biopsy; OHT, orthotopic heart transplantation.
FIGURE E1. Analyzed vascular abnormalities: A, Myocardial arteriole—endothelial cells (red arrow), muscular layer (black arrow), thin intima (green
arrow). B, Myocardial arteriole—enlarged endothelial cells (red arrows) and light and focal vacuolation (black arrow). C, Myocardial arteriole—focal in-
timal thickening (red arrow) and prominent endothelial cells (black arrow). D, Myocardial arteriole—focal muscular hypertrophy (green arrow), recent fi-
brolipoid plaque (red arrow), lipid-containing cells (black arrow), and slightly enlarged endothelial cells (white arrow).E, Myocardial arteriole—focal intimal
thickening and hyalinized arteriolar wall (black arrow). F, Myocardial arteriole—periarteriolar fibrosis. G, Myocardial arteriole—periarteriolar fibrosis col-
lagen stained green. H, Myocardial arteriole—vacuolization: hydropic degeneration (black arrows). I, Myocardial arteriole—lymphocytes inside the arteriolar
wall (green arrow).The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 1 221.e2
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Cardiothoracic Transplantation Zakliczynski et alTABLE E1. Probability of any CAV (confirmed by coronary angiography), significant CAV (critical stenosis, myocardial infarction, need of
percutaneous coronary intervention, or death caused by CAV), and death from all causes in patients with particular risk factors, including
classic risk factors of ischemic heart disease, high predisposition toward AR, and 12- and 36-month EMB findings (odds ratios, 95% confidence
intervals, and P values)
Probability of any CAV Probability of significant CAV Probability of death
Risk factor n (þ) n () OR 95% CI P value OR 95% CI P value OR 95% CI P value
Clinical risk factors
Sex (male) 63 5 2.66 0.41–17.15 NS 2.42 0.25–23.01 NS 1.65 0.26–10.56 NS
Age (40 y) 47 21 1.28 0.43–3.81 NS 0.78 0.26–2.31 NS 0.95 0.34–2.66 NS
Age (50 y) 21 47 0.55 0.19–1.58 NS 1.12 0.38–3.26 NS 1.39 0.49–3.92 NS
Ischemic cardiomyopathy 35 33 2.12 0.77–5.83 NS 2.67 0.94–7.59 NS 1.26 0.49–3.27 NS
BMI  25 34 34 0.88 0.32–2.38 NS 1.30 0.48–3.55 NS 0.55 0.21–1.45 NS
Diabetes mellitus 11 57 1.08 0.28–4.14 NS 1.58 0.43–5.85 NS 0.75 0.21–2.74 NS
Arterial hypertension 30 38 0.85 0.31–2.30 NS 1.02 0.37–2.80 NS 1.85 0.70–4.89 NS
Hyperlipidemia 45 23 1.61 0.57–4.58 NS 1.85 0.61–5.63 NS 1.63 0.59–4.47 NS
More than 2 episodes of significant AR 20 48 1.64 0.53–5.04 NS 0.92 0.31–2.75 NS 0.69 0.24–1.97 NS
Significant AR 1 y after OHT 18 50 1.86 0.57–6.05 NS 2.20 0.73–6.66 NS 0.36 0.12–1.12 NS
Abnormalities in 2-week EMB
Prominent endothelial cells 25 43 0.75 0.27–2.09 NS 0.57 0.20–1.66 NS 0.80 0.30–2.15 NS
Degeneration of endothelium 11 57 1.47 0.34–6.28 NS 0.68 0.16–2.92 NS 0.75 0.21–2.74 NS
Thickening of muscle layer 16 52 0.89 0.27–2.89 NS 1.75 0.54–5.64 NS 2.57 0.78–8.43 NS
Thickening of basal membrane and muscle
layer
7 61 0.45 0.09–2.18 NS 1.36 0.28–6.65 NS 0.68 0.14–3.30 NS
Lymphocytes inside arterial wall 4 64 1.89 0.19–19.28 NS 5.86 0.57–59.81 NS — — NS
Periarteriolar fibrosis 22 46 0.88 0.30–2.58 NS 0.92 0.31–2.75 NS 0.70 0.25–1.94 NS
Diminished lumen 8 60 0.79 0.16–3.88 NS 0.67 0.12–3.77 NS 1.67 0.37–7.61 NS
Lipofuscin presence 2 66 — — NS 1.74 0.10–29.15 NS — — NS
Abnormalities in 1-year EMB
Prominent endothelial cells 39 29 0.55 0.19–1.54 NS 0.42 0.15–1.18 .0977 0.37 0.14–0.99 .0457
Degeneration of endothelium 38 30 1.69 0.62–4.62 NS 0.89 0.32–2.43 NS 0.69 0.26–1.80 NS
Thickening of muscle layer 13 55 0.65 0.19–2.22 NS 1.67 0.49–5.70 NS 0.52 0.15–1.79 NS
Thickening of basal membrane and muscle
layer
2 66 — — NS — — NS 0.94 0.06–15.69 NS
Lymphocytes inside arterial wall 8 60 0.57 0.13–2.51 NS 0.22 0.03–1.89 NS 0.27 0.05–1.46 NS
Periarteriolar fibrosis 38 30 1.00 0.37–2.73 NS 0.68 0.25–1.87 NS 1.11 0.43–2.90 NS
Diminished lumen 6 62 0.58 0.11–3.12 NS 0.86 0.15–5.10 NS 0.44 0.07–2.58 NS
Lipofuscin presence 23 45 1.48 0.50–4.37 NS 2.38 0.83–6.86 NS 1.78 0.64–4.94 NS
Abnormalities in 3-year EMB
Prominent endothelial cells 33 31 0.71 0.25–2.00 NS 0.53 0.18–1.54 NS 0.47 0.17–1.27 NS
Degeneration of endothelium 37 27 0.83 0.29–2.35 NS 0.47 0.16–1.38 NS 0.79 0.29–2.13 NS
Thickening of muscle layer 9 55 0.76 0.18–3.16 NS 0.51 0.10–2.71 NS 1.39 0.34–5.75 NS
Thickening of basal membrane and muscle
layer
5 59 0.94 0.15–6.10 NS 1.33 0.21–8.67 NS 1.66 0.26–10.68 NS
Lymphocytes inside arterial wall 14 50 0.38 0.11–1.27 NS 0.73 0.20–2.68 NS 0.34 0.09–1.23 NS
Periarteriolar fibrosis 37 27 2.69 0.94–7.71 .0621 1.04 0.36–3.02 NS 5.27 1.77–15.75 .0047
Diminished lumen 1 63 — — NS — — NS — — NS
Lipofuscin presence 30 34 1.56 0.55–4.36 NS 0.95 0.33–2.74 NS 0.88 0.33–2.34 NS
CAV, Coronary vasculopathy; AR, acute rejection; OHT, orthotopic heart transplantation; EMB, endomyocardial biopsy; BMI, body mass index; NS, not significant; OR, odds ratio;
CI, confidence interval.221.e3 The Journal of Thoracic and Cardiovascular Surgery c July 2009
